Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Why Did Microsoft (NASDAQ:MSFT) Hold Steady Through a Global Outage?

● Fiscal first-quarterRevenuerose 19% to $92.3 billion, with Azure growth at 48%.

Nitish Kishor | 16 November 2026

Micron Technology (NASDAQ:MU) Stock: Memory Names Slip as Nvidia Turmoil Spreads

● Fiscal fourth-quarterRevenuerose 379.3% to $54.23 billion on the memory shortage.

Nitish Kishor | 16 November 2026

Nebius Group (NASDAQ:NBIS) Extends Its Slide After a Guidance Reset and Higher Spending Plans

● Planned 2026Capitalspending rose to about $27 billion from $20 billion to $25 billion.

Nitish Kishor | 16 November 2026

What Drove Heavy Trading in Nvidia (NASDAQ:NVDA) After Jensen Huang's Exit?

● HSBC downgraded Nvidia to Hold, andMarket Valueended near $3.92 trillion.

Nitish Kishor | 16 November 2026

Why Is Sandisk (NASDAQ:SNDK) Falling Ahead of Its 8-for-1 Stock Split?

● Fiscal first-quarterRevenuerose 378% to $11.03 billion, with an 85.1% gross margin.

Nitish Kishor | 16 November 2026

SpaceX (NASDAQ:SPCX) Stays Busy Ahead of Starship Flight 15 as Merger Scrutiny Builds

● Third-quarterRevenuerose 161% to $14.6 billion, withNet Incomeof $4.4 billion.

Nitish Kishor | 16 November 2026

Tesla (NASDAQ:TSLA) Cools After a Robotaxi-Led Rally as Merger Questions Linger

● Third-quarterRevenuewas flat at $28.05 billion, whileOperating Marginfell to 2.6%.

Nitish Kishor | 16 November 2026

BioLineRx GLIX1 Fourth Cohort Initiated at SNO 2026

BioLineRx Ltd. and Hemispherian AS issued an 8-K-style press release on November 16, 2026, announcing the presentation of two GLIX1 posters at the 31st Society for Neuro-Oncology Annual Meeting and disclosing that dosing had been initiated in the fourth cohort of the ongoing Phase …

Anjali Anand | 16 November 2026

Xtant Medical Q3 2026: Revenue Falls to $24.3M, Guidance Withdrawn

Xtant Medical Holdings, Inc. (NYSE American:XTNT) reported third-quarter 2026 financial results on November 16, 2026, disclosing a net loss of $3.6 million, year-over-year revenue declines, and the withdrawal of its full-year 2026 financial guidance amid an ongoing Board-led strategic review.

Nitish Kishor | 16 November 2026

Bain Capital Life Sciences Cuts Heartflow Stake to 5.06%

BCLS Fund III Investments, LP filed Amendment No. 3 to a Schedule 13G with the SEC on November 16, 2026, disclosing its beneficial ownership of common stock in Heartflow, Inc. as of September 30, 2026.

Nitish Kishor | 16 November 2026
Support

Hi! How can we help you today?

Loading…